Connect Biopharma Holdings Limited [•] American Depositary Shares Representing [•] Ordinary Shares (Par Value $0.000174 Per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • March 12th, 2021 • Connect Biopharma Holdings LTD • Pharmaceutical preparations • New York
Contract Type FiledMarch 12th, 2021 Company Industry Jurisdiction
DEPOSIT AGREEMENT by and among CONNECT BIOPHARMA HOLDINGS LIMITED as Issuer, DEUTSCHE BANK TRUST COMPANY AMERICAS as Depositary, AND THE HOLDERS AND BENEFICIAL OWNERS OF AMERICAN DEPOSITARY SHARES EVIDENCED BY AMERICAN DEPOSITARY RECEIPTS ISSUED...Deposit Agreement • March 12th, 2021 • Connect Biopharma Holdings LTD • Pharmaceutical preparations • New York
Contract Type FiledMarch 12th, 2021 Company Industry JurisdictionDEPOSIT AGREEMENT, dated as of March [•], 2021, by and among (i) Connect Biopharma Holdings Limited, a company incorporated in the Cayman Islands, with its principal executive office at Science and Technology Park, East R&D Building, 3rd Floor, 6 Beijing West Road, Taicang, Jiangsu Province, China 215400 and its registered office at Maples Corporate Services Limited at PO Box 309, Ugland House, Grand Cayman, KY1-1104, Cayman Islands (together with its successors, the “Company”), (ii) Deutsche Bank Trust Company Americas, an indirect wholly owned subsidiary of Deutsche Bank A.G., acting in its capacity as depositary, with its principal office at 60 Wall Street, New York, NY 10005, United States of America (the “Depositary”, which term shall include any successor depositary hereunder) and (iii) all Holders and Beneficial Owners of American Depositary Shares evidenced by American Depositary Receipts issued hereunder (all such capitalized terms as hereinafter defined).
FORM OF INDEMNIFICATION AGREEMENTIndemnification Agreement • March 12th, 2021 • Connect Biopharma Holdings LTD • Pharmaceutical preparations • Hong Kong
Contract Type FiledMarch 12th, 2021 Company Industry JurisdictionTHIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into this _________, 2021, between Connect Biopharma Holdings Limited, a Cayman Islands company (the “Company”), and (the “Indemnitee”).